ContraFect Corporation stock is up 238.57% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 December’s closed higher than November.
ContraFect Corporation discovers and develops therapeutic protein and antibody products. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. CF-370, an investigational anti-bacterial therapeutic candidate, is in clinical trials to treat pseudomonas aeruginosa infections.